Visceral adiposity index is associated with significant fibrosis in patients with non-alcoholic fatty liver disease
- PMID: 22117531
- DOI: 10.1111/j.1365-2036.2011.04929.x
Visceral adiposity index is associated with significant fibrosis in patients with non-alcoholic fatty liver disease
Abstract
Background: Metabolic factors have been associated with liver damage in patients with non-alcoholic fatty liver disease (NAFLD).
Aims: To test a new marker of adipose dysfunction, the visceral adiposity index (VAI), in NAFLD patients to assess whether or not it is associated with host factors, and to investigate a potential correlation with histological findings.
Methods: One hundred and forty-two consecutive NAFLD patients were evaluated by liver biopsy, and clinical and metabolic measurements, including insulin resistance with the homeostasis model assessment (HOMA), and VAI by using waist circumference, body mass index, triglycerides and HDL. Serum levels of TNFα, IL-6, adiponectin and leptin were also assessed. All biopsies were scored for NAFLD activity score (NAS) and its components, and for staging (Kleiner).
Results: By multiple linear regression analysis, VAI was independently associated with higher HOMA (P = 0.04), and fibrosis (P = 0.04). In addition, an independent association was found between higher VAI and lower adiponectin levels (P = 0.002). Higher HOMA (OR 1.149, 95% CI 1.003-1.316, P = 0.04), higher VAI (OR 1.446, 95% CI 1.023-2.043, P = 0.03), lobular inflammation (OR 3.777, 95% CI 1.771-8.051, P = 0.001), and ballooning (OR 2.884, 95% CI 1.231-6.757, P = 0.01) were correlated with significant fibrosis (F2-F4) on multiple logistic regression analysis. In particular, the prevalence of significant fibrosis progressively increased from patients with a VAI ≤ 2.1 and HOMA ≤ 3.4 (26%) to those with a VAI > 2.1 and HOMA > 3.4 (83%).
Conclusions: In NAFLD patients, visceral adiposity index is an expression of both qualitative and quantitative adipose tissue dysfunction and, together with insulin resistance, is independently correlated with significant fibrosis.
© 2011 Blackwell Publishing Ltd.
Comment in
-
Visceral adiposity index and exercise in non-alcoholic fatty liver disease.Aliment Pharmacol Ther. 2012 Feb;35(4):489; author reply 490. doi: 10.1111/j.1365-2036.2011.04963.x. Aliment Pharmacol Ther. 2012. PMID: 22248426 No abstract available.
-
Letter: Is visceral adiposity index a predictor of liver histology in patients with non-alcoholic fatty liver disease?Aliment Pharmacol Ther. 2013 Mar;37(5):583. doi: 10.1111/apt.12210. Aliment Pharmacol Ther. 2013. PMID: 23369167 No abstract available.
Similar articles
-
Visceral adiposity index is not a predictor of liver histology in patients with non-alcoholic fatty liver disease.J Hepatol. 2012 Aug;57(2):392-8. doi: 10.1016/j.jhep.2012.03.013. Epub 2012 Apr 17. J Hepatol. 2012. PMID: 22521350
-
Risk of nonalcoholic steatohepatitis and fibrosis in patients with nonalcoholic fatty liver disease and low visceral adiposity.J Hepatol. 2011 Jun;54(6):1244-9. doi: 10.1016/j.jhep.2010.09.037. Epub 2010 Nov 11. J Hepatol. 2011. PMID: 21145841
-
Insulin Resistance but Not Visceral Adiposity Index Is Associated with Liver Fibrosis in Nondiabetic Subjects with Nonalcoholic Fatty Liver Disease.Metab Syndr Relat Disord. 2015 Sep;13(7):319-25. doi: 10.1089/met.2015.0018. Epub 2015 May 26. Metab Syndr Relat Disord. 2015. PMID: 26011302
-
Non-invasive assessment of fibrosis in non-alcoholic fatty liver disease.Ann Hepatol. 2009 Apr-Jun;8(2):89-94. Ann Hepatol. 2009. PMID: 19502649 Review.
-
The Visceral Adiposity Index in Non-Alcoholic Fatty Liver Disease and Liver Fibrosis-Systematic Review and Meta-Analysis.Biomedicines. 2021 Dec 13;9(12):1890. doi: 10.3390/biomedicines9121890. Biomedicines. 2021. PMID: 34944706 Free PMC article. Review.
Cited by
-
Nonalcoholic Fatty Liver Disease and Staging of Hepatic Fibrosis.Adv Exp Med Biol. 2024;1460:539-574. doi: 10.1007/978-3-031-63657-8_18. Adv Exp Med Biol. 2024. PMID: 39287864 Review.
-
Liver and cardiovascular outcomes in lean non-alcoholic fatty liver disease: an updated systematic review and meta-analysis of about 1 million individuals.Hepatol Int. 2024 Oct;18(5):1396-1415. doi: 10.1007/s12072-024-10716-z. Epub 2024 Aug 8. Hepatol Int. 2024. PMID: 39117942
-
Effect of sustained decreases in sedentary time and increases in physical activity on liver enzymes and indices in type 2 diabetes.Front Endocrinol (Lausanne). 2024 May 24;15:1393859. doi: 10.3389/fendo.2024.1393859. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 38854689 Free PMC article. Clinical Trial.
-
Advances in the Pathogenesis of Metabolic Liver Disease-Related Hepatocellular Carcinoma.J Hepatocell Carcinoma. 2024 Mar 19;11:581-594. doi: 10.2147/JHC.S450460. eCollection 2024. J Hepatocell Carcinoma. 2024. PMID: 38525158 Free PMC article. Review.
-
Gender difference in association between low muscle mass and risk of non-alcoholic fatty liver disease among Chinese adults with visceral obesity.Front Nutr. 2023 Jan 13;10:1026054. doi: 10.3389/fnut.2023.1026054. eCollection 2023. Front Nutr. 2023. PMID: 36713086 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous